ICUI vs TFX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: TFX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ICUI and TFX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ICUI and TFX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

ICU Medical makes the plumbing of hospital drug delivery. Its Consumables segment sells IV sets, needle-free connectors (the CLAVE family it has built its reputation on), oncology and vascular access products, and tracheostomy devices. Infusion Systems sells the large volume, syringe and ambulatory pumps that push those fluids, including the Plum Duo and Plum Solo platforms plus the LifeShield safety software layer and the CADD and Medfusion pumps inherited from Smiths Medical. Vital Care is the catch-all for temperature management, respiratory, cardiac monitoring and the IV solutions business, most of which now sits inside Otsuka ICU Medical LLC, the joint venture formed in May 2025 when ICU sold 60% of IV Solutions to Otsuka Pharmaceutical Factory America and kept a 40% stake. Revenue for full year 2025 was about $2.23 billion, down roughly 6% on a reported basis almost entirely because of that deconsolidation, with Consumables at about $1.11 billion, Infusion Systems at about $684 million and Vital Care at about $438 million.

Full ICUI guide

Teleflex Incorporated designs and manufactures single-use medical devices used in critical care and surgery, sold mainly to hospitals through a large disposable-product installed base. After a portfolio overhaul announced in 2025 and executed through 2026, the continuing business reports in three segments: Vascular Access (the Arrow line of central venous and arterial catheters and related kits), Interventional (complex catheters, the MANTA large-bore closure device, intra-aortic balloon pumps, and the newly acquired Biotronik coronary and peripheral range including the ultrathin Orsiro Mission drug-eluting stent, the PK Papyrus covered stent, and the Pantera Lux and Passeo-18 Lux drug-coated balloons), and Surgical (ligation clips, closure systems, and instruments). The businesses being sold, Acute Care, Interventional Urology (home of UroLift), and OEM contract manufacturing, are reported as discontinued operations.

Full TFX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ICUI drivers: The Infusion Systems replacement cycle; Gross margin recovery.
• TFX drivers: Biotronik vascular intervention integration; Portfolio simplification and capital returns.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Regulatory and quality exposure is the most specific risk. For TFX, the Acute Care and Interventional Urology sale to Intersurgical drew a Federal Trade Commission second request in March 2026, so that leg of the divestiture carries real timing and completion risk even though the OEM sale cleared.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ICUI if you believe its drivers more; TFX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ICUI and TFX guides.

ICUI. At roughly $165 per share on October 16, 2026, ICUI trades near 19 times the midpoint of its guided adjusted EPS, about 17 times 2027 consensus, and around 16 times enterprise value to trailing EBITDA, a discount to large-cap medical device peers that reflects the leverage plus the unfinished integration. The gap between GAAP and adjusted numbers is unusually wide here, with a trailing GAAP P/E near 139 and FY2026 GAAP EPS guided to roughly $2.89 to $3.29 (raised from roughly $1.03 to $1.74), because acquisition amortization, restructuring and integration costs are excluded from the adjusted figures. ICU Medical pays no dividend and directs its cash toward debt repayment instead.

TFX. Trailing P/E is not meaningful because GAAP earnings are still negative on divestiture and impairment charges, so the market prices Teleflex off adjusted EPS and forward estimates. At roughly ~$130 the shares sit mid-range in a ~$100 to ~$145 fifty-two week band and trade near ~12x consensus 2027 EPS, below where large-cap medtech peers typically trade. Third quarter 2026 results are due October 29, 2026, with consensus near ~$1.89 of adjusted EPS on ~$565 million of revenue.

Headline figures (approximate, October 2026): ICUI shows revenue (ttm) ~$2.16 billion (FY2025 ~$2.21 billion as reported), q2 2026 revenue ~$548-552 million, ~6% organic growth, adjusted ebitda (fy2026 guide) ~$415 million to ~$435 million, adjusted eps (fy2026 guide) ~$8.60 to ~$9.00; Q2 actual ~$2.37 vs ~$1.91 expected; TFX shows revenue (ttm) ~$2.25B (+~29% yoy in Q2, Biotronik-boosted), q2 2026 revenue ~$570M; adj. EPS ~$1.76 vs ~$1.28 est., margins (gross / operating) ~55% / ~10%, eps (trailing gaap / 2026 est.) ~-$8.48 / ~$7.08.

ICUI and TFX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ICUI and TFX exposure against your real portfolio. It is not an investment adviser.